Earnings summaries and quarterly performance for Mereo BioPharma Group.
Executive leadership at Mereo BioPharma Group.
Board of directors at Mereo BioPharma Group.
AE
Anders Ekblom
Detailed
Director
AJ
Annalisa Jenkins
Detailed
Director
DS
Daniel Shames
Detailed
Director
DP
Deepika Pakianathan
Detailed
Director
JB
Jeremy Bender
Detailed
Director
JR
Justin Roberts
Detailed
Director
MY
Marc Yoskowitz
Detailed
Director
MW
Michael Wyzga
Detailed
Chairman of the Board and Director
PJ
Pierre Jacquet
Detailed
Director
Research analysts covering Mereo BioPharma Group.
Recent press releases and 8-K filings for MREO.
Mereo BioPharma Group Faces Class Action Lawsuit
MREO
Legal Proceedings
Profit Warning
- A class action lawsuit has been filed against Mereo BioPharma Group plc (MREO), alleging securities fraud or other unlawful business practices by the company and its officers/directors.
- Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to ask the Court to appoint them as Lead Plaintiff.
- The lawsuit follows two significant drops in Mereo's American Depositary Receipt (ADR) price: a 42.52% decline on July 10, 2025, and an 87.7% decline on December 29, 2025.
- These declines occurred after announcements that the Orbit and Cosmic Phase 3 studies did not achieve statistical significance for their primary endpoints.
1 day ago
Mereo BioPharma Faces Class Action Lawsuit Over Clinical Trial Disclosures
MREO
Legal Proceedings
- A class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO), alleging the company and certain officers made materially false and misleading statements regarding the prospects for the setrusumab drug program.
- The lawsuit contends that Mereo violated Sections 10(b) and 20(a) of the Securities Exchange Act concerning the Phase 3 ORBIT and COSMIC clinical trials for setrusumab, with the alleged misleading statements occurring between June 5, 2023, and December 26, 2025.
- Plaintiffs allege that executives knew or recklessly disregarded internal data contradicting optimistic statements and that an artificially inflated stock price benefited fundraising, including a June 2024 financing.
- The deadline for shareholders to file motions for lead plaintiff in the lawsuit is April 6, 2026.
3 days ago
Mereo BioPharma Group Faces Class Action Lawsuit
MREO
Legal Proceedings
- A class action lawsuit has been filed against Mereo BioPharma Group plc concerning alleged securities fraud or other unlawful business practices by the company and certain officers and/or directors.
- Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to ask the Court to appoint them as Lead Plaintiff.
- The lawsuit follows significant drops in Mereo's American Depositary Receipt (ADR) price, including a 42.52% fall on July 10, 2025, and an 87.7% fall on December 29, 2025.
- These price declines occurred after announcements that the company's Phase 3 Orbit and Cosmic studies did not achieve statistical significance for their primary endpoints by December 29, 2025.
3 days ago
Mereo BioPharma Group Faces Class Action Lawsuit
MREO
Legal Proceedings
- A class action lawsuit has been filed against Mereo BioPharma Group plc (MREO), alleging securities fraud or unlawful business practices by the company and its officers/directors.
- Investors have until April 6, 2026, to ask the Court to appoint them as Lead Plaintiff for the class.
- The lawsuit follows significant drops in Mereo's American Depositary Receipt (ADR) price, including a 42.52% decline on July 10, 2025, and an 87.7% decline on December 29, 2025, after negative updates on its Phase 3 Orbit and Cosmic studies.
Feb 20, 2026, 1:04 AM
Mereo BioPharma Group Faces Lawsuit Following Phase 3 Trial Disclosures
MREO
Legal Proceedings
Demand Weakening
Profit Warning
- Mereo BioPharma Group plc (MREO) shares declined 87.7%, from $2.31 to $0.29 per ADS, on December 29, 2025, following corrective disclosures.
- This significant drop was due to the revelation that neither the ORBIT nor COSMIC Phase 3 clinical trials achieved statistical significance for their primary endpoints.
- A lawsuit has been filed, alleging investor damages from artificial inflation in the share price, with the deadline to move for lead plaintiff set for April 6, 2026.
Feb 19, 2026, 9:00 PM
Mereo BioPharma Group plc Receives Nasdaq Minimum Bid Price Non-Compliance Notification
MREO
Delisting/Listing Issues
- On February 17, 2026, Mereo BioPharma Group plc received a notification from Nasdaq stating that its American Depositary Shares (ADSs) failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- The company has a 180-calendar-day compliance period, until August 17, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- This notification does not result in immediate delisting, and the ADSs will continue to trade uninterrupted under the symbol "MREO".
- Mereo BioPharma Group plc intends to monitor the closing bid price of its ADSs, and its business operations are not affected by the receipt of this notification letter.
Feb 17, 2026, 9:30 PM
Mereo BioPharma Group Faces Class Action Lawsuit Over Securities Fraud Allegations
MREO
Legal Proceedings
- A class action lawsuit has been filed against Mereo BioPharma Group plc (MREO), alleging securities fraud or other unlawful business practices.
- The lawsuit stems from significant drops in Mereo's American Depositary Receipt (ADR) price following announcements regarding its Phase 3 Orbit and Cosmic studies.
- On July 10, 2025, Mereo's ADR price fell 42.52% after an update on the Orbit study.
- On December 29, 2025, the ADR price further dropped 87.7% after both the Orbit and Cosmic Phase 3 studies failed to achieve statistical significance for their primary endpoints.
- Investors have until April 6, 2026, to ask the Court to appoint them as Lead Plaintiff for the class.
Feb 17, 2026, 9:26 PM
Mereo BioPharma Group Faces Class Action Lawsuit
MREO
Legal Proceedings
Profit Warning
- A class action lawsuit has been filed against Mereo BioPharma Group plc (MREO) concerning alleged securities fraud or unlawful business practices.
- The lawsuit highlights significant stock price declines, including a 42.52% drop on July 10, 2025, and an 87.7% drop on December 29, 2025, following negative updates on its Phase 3 Orbit and Cosmic studies.
- Investors have until April 6, 2026, to apply to be appointed as Lead Plaintiff in the class action.
Feb 12, 2026, 11:51 PM
Mereo BioPharma Provides Corporate Update and Revised Cash Runway Guidance
MREO
Guidance Update
New Projects/Investments
- Mereo BioPharma reported a cash balance of approximately $41 million as of December 31, 2025, and updated its cash runway guidance to mid-2027.
- The Phase 3 Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta did not achieve statistical significance for their primary endpoints, though they showed strong statistical significance for improvement in bone mineral density. Further analyses are ongoing to determine the path forward.
- The company is advancing activities to support the planned initiation of a global Phase 3 pivotal study for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease, with discussions ongoing with potential partners.
- Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, is scheduled to present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Jan 12, 2026, 1:09 PM
Mereo BioPharma Reports Q3 2025 Financial Results and Corporate Highlights
MREO
Earnings
Guidance Update
New Projects/Investments
- Mereo BioPharma Group plc reported cash and cash equivalents of $48.7 million as of September 30, 2025, which is projected to fund operations into 2027.
- The company recorded a net loss of $7.0 million for the third quarter of 2025.
- Research and development expenses for Q3 2025 were $4.3 million, and general and administrative expenses were $6.0 million.
- Data from the Phase 3 Orbit and Cosmic studies of setrusumab for osteogenesis imperfecta are expected around the end of 2025.
Nov 10, 2025, 9:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more